$ヘピオン ファーマシューティカルズ(HEPA.US)$Hepion ends Phase 2 study for NASH drug due to cash restraints! Hepion Pharmaceuticals (NASDAQ:HEPA) said it has begun winding down its ASCEND-NASH Phase 2 study for its drug rencofilstat as it continues to explore strategic alternatives for the company. “We are disappointed to announce the wind-down of our Phase 2 NASHtr...
Ben Buttons :
wonder how many good drugs have fallen to the wasteside due to SS and no cash? maybe could've cured alzhiemier or something. just a thought, dam you shorts!
Trytosaveabitスレ主Ben Buttons:
Yes you are correct! Shorts drive down price! Investors look and see stock price so low that it discourages them from investing! Even though they are doing great work! Because the bottom line is people invest, ( even in great potential products ), with expectations they will get a return on taking the risk!
$ヘピオン ファーマシューティカルズ(HEPA.US)$Hepion Pharmaceuticals Expects Its Current Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Its Ops Into Q2 2025
$ヘピオン ファーマシューティカルズ(HEPA.US)$Hepion Pharmaceuticals Announces Restructuring Plan To Enhance Shareholder Value And Management Changes; Reducing Operating Costs By ~60% Going Forward. Hepion Will Incur A One-Time Restructuring Charge Of ~$400K–$800K That Will Be Recorded In Q4 Of 2023
$ヘピオン ファーマシューティカルズ(HEPA.US)$Director Wijngaard Peter purchased 5,000 shares of Common Stocks on Nov 24, 27, 2023 at an average price of $3.07 for a total value of $15,350
$ヘピオン ファーマシューティカルズ(HEPA.US)$Hepion Pharmaceuticals Announces Additional Efficacy Data For Rencofilstat Showing Improvements Among Best Reported Of Fibrosis-Reducing Compounds Benzinga· 1 min ago
$ヘピオン ファーマシューティカルズ(HEPA.US)$Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, ...
snailsister : 想請問 這樣是不是即將下市
Trytosaveabitスレ主 snailsister: Im not sure what you’re asking is coming? A bit more detail and I will try to answer for you? GL
Ben Buttons : wonder how many good drugs have fallen to the wasteside due to SS and no cash? maybe could've cured alzhiemier or something. just a thought, dam you shorts!
Trytosaveabitスレ主 Ben Buttons: Yes you are correct! Shorts drive down price! Investors look and see stock price so low that it discourages them from investing! Even though they are doing great work! Because the bottom line is people invest, ( even in great potential products ), with expectations they will get a return on taking the risk!
snailsister Trytosaveabitスレ主: 因為我持有
虧錢 剩下沒多少
もっとコメントを見る...